Halozyme grants equity awards to COO Caudill

Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs.

Rhea-AI Filing Summary

Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs. On 02/09/2026, the SVP and Chief Operating Officer acquired an option to purchase 14,047 shares of common stock at $80.48 per share, vesting over four years starting 02/09/2027.

Caudill was also granted 13,047 restricted stock units that vest 25% on the first anniversary of the grant date and 25% on each anniversary thereafter. In addition, performance stock units tied to performance periods ending December 31, 2025 became eligible to vest, covering 2,403 and 14,751 shares, subject to continued service through the third anniversary of their original PSU grant dates.

Insider Trade Summary

Grant/Award: 44,248 shares

Grant/Award 4 txns

Insider Caudill Cortney

Role SVP, CHIEF OPERATING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	14,047	$0.00	$0.00
Grant/Award	Restricted Stock Units	13,047	$0.00	$0.00
Grant/Award	Performance Stock Units	2,403	$0.00	$0.00
Grant/Award	Performance Stock Units	14,751	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 14,047 contracts (Direct); Restricted Stock Units — 13,047 contracts (Direct); Performance Stock Units — 28,637 contracts (Direct)

Footnotes (4)

1. F1. This option vests one-fourth on such date and then 1/48th monthly thereafter.
2. F2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
3. F3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
4. F4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Halozyme (HALO) disclose in Cortney Caudill’s latest Form 4?

Halozyme reported that SVP and Chief Operating Officer Cortney Caudill received new equity awards. These include a stock option, time-based restricted stock units, and performance stock units that became eligible to vest based on previously defined performance conditions and ongoing service requirements.

How many stock options were granted to Halozyme COO Cortney Caudill?

Cortney Caudill received an option to purchase 14,047 Halozyme common shares at $80.48 per share. The option vests one-fourth on the initial vesting date and then 1/48th monthly, providing long-term, performance-aligned compensation for the senior executive over a four-year period.

What restricted stock units did Cortney Caudill receive from Halozyme (HALO)?

Caudill was granted 13,047 restricted stock units representing potential Halozyme common shares. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each subsequent anniversary, aligning continued service with staged equity ownership growth over several years.

How are Halozyme performance stock units for Cortney Caudill structured?

Halozyme disclosed performance stock units previously awarded in 2024 and 2025 with a performance period ending December 31, 2025. The Form 4 reflects 2,403 and 14,751 units becoming eligible to vest, still subject to a service-based vesting requirement through each PSU grant’s third anniversary.

Does the Halozyme (HALO) Form 4 involve insider share sales by Cortney Caudill?

The Form 4 reports grants and acquisitions of derivative equity awards, not open-market sales. All reported transactions use code A for grant or other acquisition, with zero-dollar prices, indicating compensation-related awards rather than discretionary buying or selling of Halozyme common stock.

What role does Cortney Caudill hold at Halozyme and why are these equity grants important?

Cortney Caudill is Halozyme’s Senior Vice President and Chief Operating Officer. Equity awards like options, restricted stock units, and performance stock units are common tools to retain key executives and tie their compensation to long-term company performance and share price outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 09:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caudill Cortney

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$80.48	02/09/2026		A		14,047		02/09/2027(1)	02/09/2036	Common Stock	14,047	$0	14,047	D
Restricted Stock Units	$0	02/09/2026		A		13,047		02/09/2027(2)	(2)	Common Stock	13,047	$0	13,047	D
Performance Stock Units	$0	02/09/2026		A		2,403		(3)	(3)	Common Stock	2,403	$0	13,886	D
Performance Stock Units	$0	02/09/2026		A		14,751		(4)	(4)	Common Stock	14,751	$0	14,751	D

Explanation of Responses:

1. This option vests one-fourth on such date and then 1/48th monthly thereafter.

2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.